Price movement over the last 24 hours
Alcon AG vs Funko Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Funko Inc trades at $5.28 (market cap $301.53M). The key difference: Alcon AG is far larger — about 108.4× Funko Inc's market cap, and Alcon AG pays a 0.54% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| ALC | FNKO | |
|---|---|---|
Market Cap | $32.69B | $301.53M |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $5.88 |
52-Week Low | $62.02 | $2.46 |
Enterprise Value | $36.28B | $546.57M |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
FNKO trades at $5.40, down 2.0% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $200.9M, beating EPS estimates, though net income remains negative. Analyst sentiment is mixed with 42.9% buy ratings, while recent news highlights strong product launches and management changes.
The outlook is cautiously optimistic given earnings beats and revenue stabilization, but profitability challenges and negative margins pose risks. Investment opportunity lies in operational turnaround and brand strength, balanced against high debt and competitive pressures in the collectibles market.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →